ZLZoey Li

Zoey Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zoey Li has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Continuous Glucose Monitoring-Measured Glucose Levels During Oral Glucose Tolerance Testing in Pregnancy

    by Anders L. Carlson, Roy W. Beck, Zoey Li, Elizabeth Norton, Richard M. Bergenstal, Mary Johnson, Sean Dunnigan, Matthew Banfield, Katie Krumwiede, Judy Sibayan, et al.

    Background: To diagnose gestational diabetes mellitus (GDM), clinicians typically rely on the oral glucose tolerance test (OGTT). Continuous glucose monitoring (CGM) is a tool that could possibly be used to complement or replace the OGTT. Our aim is to describe CGM-derived glycemic patterns observed concurrently during the administration of a diagnostic OGTT in pregnancy. Methods: In total, 119 pregnant females underwent OGTT testing while wearing a blinded CGM sensor. Blood glucose (BG) measurements collected during the OGTT were compared with CGM-measured glucose values obtained using a Dexcom G6 Pro sensor to determine the differences between CGM-measured and BG levels during the OGTT, measure glycemic excursion during the OGTT, and determine differences in GDM diagnosis using standard BG draws during OGTT versus CGM-measured glucose levels. Results: CGM-measured glucose levels were on average higher than paired BG levels during the OGTT at each timed measurement (fasting, 1-, 2- and 3-h); fasting CGM-measured glucose levels in particular were higher than fasting BG levels by 6 ± 13 mg/dL. The median CGM minus BG-measured glycemic excursion during the OGTT was 12 and 4 mg/dL for the 75 g and 100 g OGTT, respectively. Of 28 participants diagnosed with GDM based on OGTT BG levels, 24 (86%) participants would have been diagnosed as GDM using CGM with BG-based thresholds; of 91 participants not diagnosed with GDM, 54 (59%) would also have not been diagnosed with GDM using CGM. Conclusions: CGM glucose measurements using Dexcom G6 Pro tended to be slightly higher than BG values during an OGTT, leading to more participants who would have been diagnosed with GDM if the BG-based OGTT thresholds were applied to these CGM-measured glucose values. When CGM is used for GDM diagnosis, diagnostic glucose criteria may need to be specific for the type of sensor used accounting for any bias in glucose measurement.


  • Sex Differences in Glycemia and Self-management Strategies for Exercise in an Active Adult Cohort With Type 1 Diabetes

    by Jane E Yardley, Zoey Li, Dessi P Zaharieva, Michael C Riddell, Robin L Gal, Peter Calhoun

    Objective: To examine potential differences in glucose levels during and after exercise between sexes in adults with type 1 diabetes. Methods: The Type 1 Diabetes Exercise Initiative study was a prospective, 4-week free-living observational study in adults with type 1 diabetes. Ninety-one females were matched on age and insulin modality to 91 males. Participants completed exercise study videos and personal exercise sessions. Study-collected food, insulin, exercise, and glucose data surrounding exercise and on sedentary days were compared between sexes to examine how they impact glucose levels during and after exercise. Results: Female participants had higher glucose levels than male participants when starting study exercise (8.5 ± 2.8 vs 8.0 ± 2.8 mmol/L, P = .01) and when starting personal exercise activities (8.4 ± 2.9 vs 7.8 ± 2.7 mmol/L; P = .05). Glucose declines during study exercise were comparable between female and male participants (adjusted mean: −0.8 vs −1.0 mmol/L, respectively; P = .11), but smaller in female participants during personal exercise (adjusted mean: −0.9 vs −1.4 mmol/L; P < .001). Twenty-four-hour mean glucose levels were also higher in female participants on sedentary days (P = .04). Daily macronutrient consumption was similar between sexes after adjusting for weight, as were food, exercise, and insulin habits surrounding exercise. Conclusion: Female participants had higher preexercise glucose levels compared to male participants and smaller glucose declines during personal exercise, but there were no observable differences in food, exercise, and insulin habits.


  • Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Perinatal Complications

    by Zoey Li, Roy Beck, Celeste Durnwald, Anders Carlson, Elizabeth Norton, Richard Bergenstal, Mary Johnson, Sean Dunnigan, Matthew Banfield, Katie Krumwiede, et al.

    Objective: To assess the performance of continuous glucose monitoring (CGM)-measured glycemic metrics in predicting development of gestational diabetes mellitus (GDM) and select perinatal complications. Research Methods: In a prospective observational study, CGM data were collected from 760 pregnant females throughout gestation after study enrollment. GDM was diagnosed using the oral glucose tolerance test (OGTT) at 24–34 weeks of gestation. Predictive models were built using logistic and elastic net regression. Predictive performance was assessed by the area under the receiver-operating characteristic (AUROC) curve. Results: The AUROCs of using second trimester percent time >140 mg/dL (TA140) and week 13–14 TA140 in predicting GDM were 0.81 and 0.74, respectively. The AUROCs for predicting large-for-gestational-age (LGA) births and hypertensive disorders of pregnancy (HDP) using second trimester TA140 were both 0.58. When matching the specificity of OGTT, a model using TA140 in weeks 13–14 achieved similar sensitivity to OGTT in predicting HDP (13% vs. 10%, respectively) and LGA (6% for both methods). Elastic net also demonstrated similar AUROC and diagnostic performance with no meaningful improvement by using multiple predictors. Conclusion: CGM-measured hyperglycemic metrics such as TA140 predicted GDM with high AUROCs as early as 13–14 weeks of gestation. These metrics were also similar statistically to the OGTT at 24–34 weeks in predicting perinatal complications, although sensitivity was low for both. CGM could potentially be used as an early screening tool for elevated hyperglycemia during gestation, which could be used in addition to or instead of the OGTT.


  • Changing Glucose Levels During the Menstrual Cycle as Observed in Adults in the Type 1 Diabetes Exercise Initiative Study

    by Zoey Li, Jane E. Yardley, Dessi P. Zaharieva, Michael C. Riddell, Robin L. Gal, Peter Calhoun


  • Open Access

    Glucose levels measured with continuous glucose monitoring in uncomplicated pregnancies

    by Anders L Carlson, Roy W Beck, Zoey Li, Elizabeth Norton, Richard M Bergenstal, Mary Johnson, Sean Dunnigan, Matthew Banfield, Katie J Krumwiede, Judy R Sibayan, et al.

    Introduction: To characterize glucose levels during uncomplicated pregnancies, defined as pregnancy with a hemoglobin A1c 2) and wore Dexcom G6 continuous glucose monitoring (CGM) devices throughout the observed gestational period. Mealtimes were voluntarily recorded. Glycemic levels during gestation were characterized using CGM-measured glycemic metrics. Results: Participants wore CGM for a median of 123 days each. Glucose levels were nearly stable throughout all three trimesters in uncomplicated pregnancies. Overall mean±SD glucose during gestation was 98±7 mg/dL (5.4±0.4 mmol/L), median per cent time 63–120 mg/dL (3.5–6.7 mmol/L) was 86% (IQR: 82–89%), median per cent time 120 mg/dL (6.7 mmol/L) was 11%, and median per cent time >140 mg/dL (7.8 mmol/L) was 2.5%. Mean post-prandial peak glucose was 126±22 mg/dL (7.0±1.2 mmol/L), and mean post-prandial glycemic excursion was 36±22 mg/dL (2.0±1.2 mmol/L). Higher mean glucose levels were low to moderately associated with pregnant individuals with higher BMIs (103±6 mg/dL (5.7±0.3 mmol/L) for BMI ≥30.0 kg/m2 vs 96±7 mg/dL (5.3±0.4 mmol/L) for BMI 18.5–2, r=0.35). Conclusions: Mean glucose levels and time 63–120 mg/dL (3.5–6.7 mmol/L) remained nearly stable throughout pregnancy and values above 140 mg/dL (7.8 mmol/L) were rare. Mean glucose levels in pregnancy trend higher as BMI increases into the overweight/obesity range. The glycemic metrics reported during uncomplicated pregnancies represent treatment targets for pregnant individuals.


  • Factors Affecting Reproducibility of Change in Glucose During Exercise: Results From the Type 1 Diabetes and EXercise Initiative

    by Zoey Li, Peter Calhoun, Michael R. Rickels, Robin L. Gal, Roy W. Beck, Peter G. Jacobs, Mark A. Clements, Susana R. Patton, Jessica R. Castle, Corby K. Martin, et al.

    Aims: To evaluate factors affecting within-participant reproducibility in glycemic response to different forms of exercise. Methods: Structured exercise sessions ~30 minutes in length from the Type 1 Diabetes Exercise Initiative (T1DEXI) study were used to assess within-participant glycemic variability during and after exercise. The effect of several pre-exercise factors on the within-participant glycemic variability was evaluated. Results: Data from 476 adults with type 1 diabetes were analyzed. A participant’s change in glucose during exercise was reproducible within 15 mg/dL of the participant’s other exercise sessions only 32% of the time. Participants who exercised with lower and more consistent glucose level, insulin on board (IOB), and carbohydrate intake at exercise start had less variability in glycemic change during exercise. Participants with lower mean glucose ( P < .001), lower glucose coefficient of variation (CV) ( P < .001), and lower % time P = .005) on sedentary days had less variable 24-hour post-exercise mean glucose. Conclusions: Reproducibility of change in glucose during exercise was low in this cohort of adults with T1D, but more consistency in pre-exercise glucose levels, IOB, and carbohydrates may increase this reproducibility. Mean glucose variability in the 24 hours after exercise is influenced more by the participant’s overall glycemic control than other modifiable factors.


  • Psychosocial Impact of the Insulin-Only iLet Bionic Pancreas for Adults, Youth, and Caregivers of Youth with Type 1 Diabetes

    by Jill Weissberg-Benchell, Anthony T. Vesco, Jenna Shapiro, Peter Calhoun, Edward R. Damiano, Steven J. Russell, Zoey Li, Firas H. El-Khatib, Katrina J. Ruedy, Courtney A. Balliro, et al.

    Objective: To evaluate the psychosocial impact and user experience for the insulin-only configuration of iLet bionic pancreas (BP) in persons 6–83 years years of age with type 1 diabetes. Research Design and Methods: In this multicenter, randomized controlled, 13-week trial, 275 adults (221 randomly assigned to the BP group and 54 to the standard of care [SC] group) and 165 youth and their caregivers (112 randomly assigned to the BP group and 53 to the SC group) completed psychosocial questionnaires at baseline, mid-study, and the end of the trial. Results: In all age groups, most participants would recommend using the BP, including those with previous experience using automated insulin delivery devices. Similarly, the vast majority of participants reported a high level of perceived benefits and a low number of perceived burdens. Adult participants reported significant decreases in the fear of hypoglycemia and in diabetes-specific emotional distress, as well as improvements in their perceived well-being. Conclusion: Findings demonstrate acceptability, reduced burden, and positive psychosocial outcomes for adults. Children and teenagers also report high acceptability and reduced burden, but less clear improvements in psychosocial outcomes. Clinical Trial Registration Number: NCT04200313.


  • The Type 1 Diabetes and EXercise Initiative: Predicting Hypoglycemia Risk During Exercise for Participants with Type 1 Diabetes Using Repeated Measures Random Forest

    by Simon Bergford, Michael C. Riddell, Peter G. Jacobs, Zoey Li, Robin L. Gal, Mark A. Clements, Francis J. Doyle, Corby K. Martin, Susana R. Patton, Jessica R. Castle, et al.

    Objective: Exercise is known to increase the risk for hypoglycemia in type 1 diabetes (T1D) but predicting when it may occur remains a major challenge. The objective of this study was to develop a hypoglycemia prediction model based on a large real-world study of exercise in T1D. Research Design and Methods: Structured study-specified exercise (aerobic, interval, and resistance training videos) and free-living exercise sessions from the T1D Exercise Initiative study were used to build a model for predicting hypoglycemia, a continuous glucose monitoring value <70 mg/dL, during exercise. Repeated measures random forest (RMRF) and repeated measures logistic regression (RMLR) models were constructed to predict hypoglycemia using predictors at the start of exercise and baseline characteristics. Models were evaluated with area under the receiver operating characteristic curve (AUC) and balanced accuracy. Results: RMRF and RMLR had similar AUC (0.833 vs. 0.825, respectively) and both models had a balanced accuracy of 77%. The probability of hypoglycemia was higher for exercise sessions with lower pre-exercise glucose levels, negative pre-exercise glucose rates of change, greater percent time <70 mg/dL in the 24 h before exercise, and greater pre-exercise bolus insulin-on-board (IOB). Free-living aerobic exercises, walking/hiking, and physical labor had the highest probability of hypoglycemia, while structured exercises had the lowest probability of hypoglycemia. Conclusions: RMRF and RMLR accurately predict hypoglycemia during exercise and identify factors that increase the risk of hypoglycemia. Lower glucose, decreasing levels of glucose before exercise, and greater pre-exercise IOB largely predict hypoglycemia risk in adults with T1D.


  • Concordance of Central Laboratory Hemoglobin A1c Measurements from Capillary Kits Compared to Venous Draws in the Insulin-Only Bionic Pancreas Pivotal Trial

    by Zoey Li, Peter Calhoun, Katrina J. Ruedy, Roy W. Beck

    Capillary hemoglobin A1c (HbA1c) collection has grown in importance due to its convenience during situations such as the coronavirus disease 2019 (COVID-19) pandemic and virtual visits. The viability of capillary blood samples as an accurate alternative to venous samples has previously only been assessed in smaller sample sizes. In this brief report, 773 paired capillary and venous samples taken from 258 study participants in the Insulin-Only Bionic Pancreas Trial were analyzed at the University of Minnesota Advanced Research and Diagnostic Laboratory and assessed for HbA1c value congruency. Results showed that 97.7% of the capillary samples were within 5% of their respective venous measurement, and R 2 between the two HbA1c sources was 0.95. These results are consistent with previous studies that also reported high concordance between capillary and venous HbA1c values using the same laboratory method, providing further evidence that capillary HbA1c measurements are an accurate alternative to venous measurements. Clinical Trial Registration number: NCT04200313.


  • Utility and Safety of Backup Insulin Regimens Generated by the Bionic Pancreas: A Randomized Study

    by Nelly Mauras, Edward R. Damiano, Firas H. El-Khatib, Martin Chase Marak, Peter Calhoun, Katrina J. Ruedy, Courtney Balliro, Zoey Li, Roy W. Beck, Steven J. Russell

    The bionic pancreas (BP) is initialized with body weight only and doses insulin autonomously without carbohydrate counting, instead using qualitative meal announcements. In case of device malfunction, the BP generates and continuously updates backup insulin doses for injection or pump users, including long-acting insulin dose, a four-period basal insulin profile, short-acting meal doses, and a glucose correction factor. Following a 13-week trial in type 1 diabetes, participants using the BP (6–83 years) completed 2–4 days, in which they were randomly assigned to their prestudy insulin regimen ( N = 147) or to follow BP-provided guidance ( N = 148). Glycemic outcomes with BP guidance were similar to those reinstituting their prestudy insulin regimen, with both groups having higher mean glucose and lower time-in-range than while using the BP during the 13-week trial. In conclusion, a backup insulin regimen automatically generated by the BP can be safely implemented if need arises to discontinue use of the BP. Clinical Trial Registry: c linicaltrials.gov; NCT04200313.